Review



anti ki67 mouse mab  (Servicebio Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Servicebio Inc anti ki67 mouse mab
    In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for <t>Ki67</t> (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.
    Anti Ki67 Mouse Mab, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ki67/pmc13191106-322-0-42?v=Servicebio+Inc
    Average 86 stars, based on 1 article reviews
    anti ki67 mouse mab - by Bioz Stars, 2026-07
    86/100 stars

    Images

    1) Product Images from "Countering postoperative immune suppression with a self-assembling dendritic cell nanovaccine"

    Article Title: Countering postoperative immune suppression with a self-assembling dendritic cell nanovaccine

    Journal: Bioactive Materials

    doi: 10.1016/j.bioactmat.2026.05.005

    In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for Ki67 (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.
    Figure Legend Snippet: In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for Ki67 (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.

    Techniques Used: In Vivo, Drug discovery, Staining, TUNEL Assay, Immunofluorescence



    Similar Products

    anti ki67 mouse mab  (Servicebio Inc)
    86
    Servicebio Inc anti ki67 mouse mab
    In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for <t>Ki67</t> (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.
    Anti Ki67 Mouse Mab, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ki67/pmc13191106-322-0-42?v=Servicebio+Inc
    Average 86 stars, based on 1 article reviews
    anti ki67 mouse mab - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    anti ki67  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc anti ki67
    In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for <t>Ki67</t> (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.
    Anti Ki67, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ki67/pmc13019076-374-0-20?v=Cell+Signaling+Technology+Inc
    Average 86 stars, based on 1 article reviews
    anti ki67 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    rabbit polyclonal anti ki67  (Servicebio Inc)
    86
    Servicebio Inc rabbit polyclonal anti ki67
    In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for <t>Ki67</t> (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.
    Rabbit Polyclonal Anti Ki67, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ki67/pmc13194166-10-0-4?v=Servicebio+Inc
    Average 86 stars, based on 1 article reviews
    rabbit polyclonal anti ki67 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    anti ki67 mouse monoclonal antibody mab  (Servicebio Inc)
    86
    Servicebio Inc anti ki67 mouse monoclonal antibody mab
    In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for <t>Ki67</t> (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.
    Anti Ki67 Mouse Monoclonal Antibody Mab, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ki67/pm42309065-335-13-25?v=Servicebio+Inc
    Average 86 stars, based on 1 article reviews
    anti ki67 mouse monoclonal antibody mab - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    resource source identifier mouse anti-ki67 mab servicebio cat#gb121141  (Servicebio Inc)
    86
    Servicebio Inc resource source identifier mouse anti-ki67 mab servicebio cat#gb121141
    In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for <t>Ki67</t> (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.
    Resource Source Identifier Mouse Anti Ki67 Mab Servicebio Cat#Gb121141, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ki67/pm42309065-274-2-9?v=Servicebio+Inc
    Average 86 stars, based on 1 article reviews
    resource source identifier mouse anti-ki67 mab servicebio cat#gb121141 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    anti human ki67  (Servicebio Inc)
    86
    Servicebio Inc anti human ki67
    In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for <t>Ki67</t> (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.
    Anti Human Ki67, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ki67/pm42310709-59-53-56?v=Servicebio+Inc
    Average 86 stars, based on 1 article reviews
    anti human ki67 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    anti ki67 antibodies  (Servicebio Inc)
    86
    Servicebio Inc anti ki67 antibodies
    In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for <t>Ki67</t> (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.
    Anti Ki67 Antibodies, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ki67/pm42279688-41-5-10?v=Servicebio+Inc
    Average 86 stars, based on 1 article reviews
    anti ki67 antibodies - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    rabbit anti ki67 antibody  (Huabio Inc)
    86
    Huabio Inc rabbit anti ki67 antibody
    Inhibition of TNKS1 expression can suppress cell proliferation in glioma xenografts.HE staining to observe cell morphology in each group (A); immunohistochemistry to detect <t>Ki-67</t> values in cells from each group (B), with an asterisk (*) indicating a significant difference compared to the TNKS1-siRNA NC group, P < 0.05. Scale bar = 50 μm.
    Rabbit Anti Ki67 Antibody, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ki67/pmc12874794-85-5-10?v=Huabio+Inc
    Average 86 stars, based on 1 article reviews
    rabbit anti ki67 antibody - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    anti antigen kiel 67 ki67  (Servicebio Inc)
    86
    Servicebio Inc anti antigen kiel 67 ki67
    Vascular formation and cell proliferation results of the induced membrane in rats. a) First-stage surgery of induced membrane technique (IMT). The white arrow refers to the bone defect, and the green arrow indicates the polymethylmethacrylate (PMMA) spacer. b) Second-stage surgery of IMT. The yellow arrow refers to the bone grafting area. c) Gross view, haematoxylin and eosin (H&E) and Masson staining results of the induced membrane. The yellow arrows indicate blood vessels. d) Immunohistostaining of platelet endothelial cell adhesion molecule-1 (CD31) in the induced membrane. The yellow arrows indicate CD31-positive vessels. e) Immunohistostaining of von Willebrand factor (vWF) in the induced membrane. The yellow arrows indicate vWF-positive vessels. f) Immunohistostaining of antigen <t>Kiel</t> <t>67</t> <t>(Ki67)</t> in the induced membrane. N = 6/group. Each value is presented as the mean (SD). *p < 0.05, **p < 0.01, ***p < 0.001 versus the Control group; #p < 0.05, ##p < 0.01, ###p < 0.001 versus the L-Naringin group.
    Anti Antigen Kiel 67 Ki67, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ki67/pmc13196827-110-25-31?v=Servicebio+Inc
    Average 86 stars, based on 1 article reviews
    anti antigen kiel 67 ki67 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for Ki67 (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.

    Journal: Bioactive Materials

    Article Title: Countering postoperative immune suppression with a self-assembling dendritic cell nanovaccine

    doi: 10.1016/j.bioactmat.2026.05.005

    Figure Lengend Snippet: In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for Ki67 (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.

    Article Snippet: Anti-Ki67 mouse mAb (Cat# GB121141-100), anti-CD3 mouse mAb (Cat# GB15014-100), FITC-conjugated goat anti-mouse IgG (H + L) (Cat# GB22301), and Cy5-conjugated goat anti-mouse IgG (H + L) (Cat# GB27301) for immunofluorescence assays, and DAB (SA-HRP) TUNEL apoptosis detection kit were supplied by Servicebio (Wuhan, China).

    Techniques: In Vivo, Drug discovery, Staining, TUNEL Assay, Immunofluorescence

    Inhibition of TNKS1 expression can suppress cell proliferation in glioma xenografts.HE staining to observe cell morphology in each group (A); immunohistochemistry to detect Ki-67 values in cells from each group (B), with an asterisk (*) indicating a significant difference compared to the TNKS1-siRNA NC group, P < 0.05. Scale bar = 50 μm.

    Journal: IBRO Neuroscience Reports

    Article Title: TNKS1 mediates the PTEN-PI3K/AKT pathway to regulate glycolysis and proliferation in gliomas

    doi: 10.1016/j.ibneur.2026.01.007

    Figure Lengend Snippet: Inhibition of TNKS1 expression can suppress cell proliferation in glioma xenografts.HE staining to observe cell morphology in each group (A); immunohistochemistry to detect Ki-67 values in cells from each group (B), with an asterisk (*) indicating a significant difference compared to the TNKS1-siRNA NC group, P < 0.05. Scale bar = 50 μm.

    Article Snippet: The primary antibody used was rabbit anti-Ki67 antibody (HA721115, 1:200, HUABIO, USA), which was incubated overnight at 4°C.

    Techniques: Inhibition, Expressing, Staining, Immunohistochemistry

    Vascular formation and cell proliferation results of the induced membrane in rats. a) First-stage surgery of induced membrane technique (IMT). The white arrow refers to the bone defect, and the green arrow indicates the polymethylmethacrylate (PMMA) spacer. b) Second-stage surgery of IMT. The yellow arrow refers to the bone grafting area. c) Gross view, haematoxylin and eosin (H&E) and Masson staining results of the induced membrane. The yellow arrows indicate blood vessels. d) Immunohistostaining of platelet endothelial cell adhesion molecule-1 (CD31) in the induced membrane. The yellow arrows indicate CD31-positive vessels. e) Immunohistostaining of von Willebrand factor (vWF) in the induced membrane. The yellow arrows indicate vWF-positive vessels. f) Immunohistostaining of antigen Kiel 67 (Ki67) in the induced membrane. N = 6/group. Each value is presented as the mean (SD). *p < 0.05, **p < 0.01, ***p < 0.001 versus the Control group; #p < 0.05, ##p < 0.01, ###p < 0.001 versus the L-Naringin group.

    Journal: Bone & Joint Research

    Article Title: Naringin targets TGF-β1-mediated angiogenesis to enhance the osteogenic effect of induced membrane

    doi: 10.1302/2046-3758.155.BJR-2025-0412.R1

    Figure Lengend Snippet: Vascular formation and cell proliferation results of the induced membrane in rats. a) First-stage surgery of induced membrane technique (IMT). The white arrow refers to the bone defect, and the green arrow indicates the polymethylmethacrylate (PMMA) spacer. b) Second-stage surgery of IMT. The yellow arrow refers to the bone grafting area. c) Gross view, haematoxylin and eosin (H&E) and Masson staining results of the induced membrane. The yellow arrows indicate blood vessels. d) Immunohistostaining of platelet endothelial cell adhesion molecule-1 (CD31) in the induced membrane. The yellow arrows indicate CD31-positive vessels. e) Immunohistostaining of von Willebrand factor (vWF) in the induced membrane. The yellow arrows indicate vWF-positive vessels. f) Immunohistostaining of antigen Kiel 67 (Ki67) in the induced membrane. N = 6/group. Each value is presented as the mean (SD). *p < 0.05, **p < 0.01, ***p < 0.001 versus the Control group; #p < 0.05, ##p < 0.01, ###p < 0.001 versus the L-Naringin group.

    Article Snippet: The slices were incubated with anti-platelet endothelial cell adhesion molecule-1 (CD31) antibody (1:50, Abcam, UK, ab281583), anti-von Willebrand factor (vWF) antibody (1:1,000, Servicebio, China, GB11020), anti-antigen Kiel 67 (Ki67) antibody (1:500, Servicebio, GB121141 ), anti-TGF-β1 antibody (1:500, Abcam, ab215715), anti-Phospho-SMAD2 antibody (p-SMAD2, 1:100, Abcam, ab188334), and anti-Phospho-SMAD3 antibody (p-SMAD3, 1:100, Bioss, China, bs-5616R).

    Techniques: Membrane, Staining, Control